Literature DB >> 30565666

High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis.

Nasrin Goolam Mahyoodeen1, Nigel J Crowther2, Tracy Snyman2, Lushen Pillay3, Mohammed Tikly1.   

Abstract

BACKGROUND: Psoriasis is associated with cardiometabolic diseases (CMDs) in Caucasians, but no data is available from sub-Saharan populations on either CMD prevalence or psoriasis risk factors. Our aim was to investigate the prevalence of CMDs in a predominantly non-Caucasian cohort of South Africans with psoriasis and to determine the principal risk factors associated with psoriasis.
METHODS: This was a cross-sectional case-control study of adult psoriasis patients (n = 103) and controls (n = 98), comparing sociodemographic, anthropometric, clinical, and biochemical characteristics. The groups were matched for gender, ethnicity, and body mass index (BMI).
RESULTS: The prevalence of metabolic syndrome (MetS) (52.4% vs. 33.7%; P = 0.007), type 2 diabetes (T2D) (25.2% vs. 4.1%; P < 0.0001), and hypertension (70.9% vs. 46.6%; P = 0.001) were all higher in the psoriasis group. High-sensitivity CRP was higher in psoriasis patients than controls (4.70 (2.00, 10.9) vs. 2.00 (1.10, 4.80) ng/ml; P < 0.0005). Multivariable logistic regression analysis showed that severe psoriasis was independently associated with MetS (odds ratio [95% CIs]: 4.42 [1.72, 11.4]; P = 0.002), T2D (11.3 [3.07, 41.3]; P = 0.0002), and hypertension (2.48 [0.97, 6.32]; P = 0.05), whilst for psoriasis the principal risk factors were smoking (3.87 [1.97, 7.63]; P < 0.0001) and hsCRP (1.05 [1.00, 1.10]; P = 0.029), with completion of high school (0.23 [0.11, 0.48]; P < 0.0001) being protective.
CONCLUSIONS: In this population, psoriasis is characterized by a high burden of CMDs, particularly in those subjects with severe psoriasis. Inflammation plays a role in the etiology of psoriasis, whilst smoking and poor education further increase disease risk.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2018        PMID: 30565666     DOI: 10.1111/ijd.14348

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

1.  Prevalence and Predictors of Abdominal Aorta Calcification in Patients With Psoriasis-A Case Control Study.

Authors:  Sofia Ramos; Sheetal Daya; Nigel J Crowther; Lushen Pillay; Mohammed Tikly; Nasrin Goolam Mahyoodeen
Journal:  Front Med (Lausanne)       Date:  2022-06-30

2.  A Matter of Fat: Body Fat Distribution and Cardiometabolic Disease in Africa.

Authors:  Nasrin Goolam Mahyoodeen; Nigel J Crowther
Journal:  Methods Mol Biol       Date:  2022

3.  Metabolic Syndrome and Psoriasis: A Case-Control Study in Kabul, Afghanistan.

Authors:  Ahmad Khalid Aalemi; Mohammad Barin Bahain; Abdul Ghafar Hamdard
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-30       Impact factor: 3.168

4.  AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings.

Authors:  Irmina Olejniczak-Staruch; Joanna Narbutt; Justyna Ceryn; Małgorzata Skibińska; Igor Bednarski; Anna Woźniacka; Joanna Sieniawska; Marzena Kraska-Gacka; Magdalena Ciążyńska; Janusz Śmigielski; Marcin Noweta; Michał Waszczykowski; Witold Owczarek; Adam Reich; Aleksandra Lesiak
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

Review 5.  "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis.

Authors:  Ranjitha Uppala; Lam C Tsoi; Paul W Harms; Bo Wang; Allison C Billi; Emanual Maverakis; J Michelle Kahlenberg; Nicole L Ward; Johann E Gudjonsson
Journal:  Cell Mol Immunol       Date:  2020-08-19       Impact factor: 11.530

6.  Effects of Dietary Protein Intake on Cutaneous and Systemic Inflammation in Mice with Acute Experimental Psoriasis.

Authors:  Tanja Knopp; Tabea Bieler; Rebecca Jung; Julia Ringen; Michael Molitor; Annika Jurda; Thomas Münzel; Ari Waisman; Philip Wenzel; Susanne Helena Karbach; Johannes Wild
Journal:  Nutrients       Date:  2021-05-31       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.